Sulforaphane.

Sulforaphane is a strong Nrf2 activator and one of the genes it turns up is glutamate-cysteine ligase, the enzyme that builds glutathione. NAC supplies cysteine, the amino acid that limits how fast that enzyme can work, so induction and substrate arrive together.

Several antioxidant enzymes that Nrf2 activation raises, including glutathione peroxidases and thioredoxin reductases, are selenoproteins carrying selenocysteine in the active site. Without adequate selenium the induced protein cannot be built in functional form, so selenium status sets the ceiling on what sulforaphane induction delivers.

Glutathione is built from cysteine, glutamate and glycine, and glycine is added in the second synthesis step. When sulforaphane raises the synthetic enzymes, glycine availability becomes a second potential bottleneck alongside cysteine.

Both compounds act on cysteine thiols of Keap1, the sensor that normally holds Nrf2 for degradation, and both feed the glutathione and thioredoxin systems downstream. Alpha lipoic acid also recycles oxidised glutathione back to its active form, which keeps the pool sulforaphane helped build in usable shape.

Broccoli sprout extract supplies glucoraphanin, the stable glucosinolate that myrosinase converts to sulforaphane. Combining the preformed isothiocyanate with the precursor gives an immediate and a slower colonic release.

Sulforaphane is conjugated to glutathione by glutathione S-transferase as the first step of the mercapturic acid pathway, and it also raises the enzymes that make new glutathione. Glutathione status therefore both consumes and is raised by sulforaphane.

Cysteine is the limiting amino acid for glutathione synthesis, and sulforaphane both induces that synthesis and consumes glutathione through conjugation. Supplying cysteine keeps the pool from being drawn down.

Both compounds modify cysteine residues on KEAP1, releasing Nrf2 to move into the nucleus and switch on phase II enzymes. Because they hit different residues, the induction is additive rather than redundant.

EGCG and sulforaphane both raise NQO1, heme oxygenase-1 and glutathione S-transferase expression through the Nrf2 route. Their combination is a standard way to raise phase II capacity without pushing one compound higher.

Silymarin activates Nrf2 and supports glutathione output in liver tissue, the same arm sulforaphane drives. They are combined in liver support formulas because the induction adds.

Sulforaphane raises glutathione conjugation while calcium D-glucarate slows beta-glucuronidase, so glucuronide conjugates stay conjugated for excretion. The pair covers two different phase II exit routes.

Molybdenum sits in the cofactor of sulfite oxidase, which converts sulfite from sulfur compound turnover to sulfate for excretion. A rising sulfur-compound load makes that step more relevant.

Quercetin oxidation products modify KEAP1 cysteines much as sulforaphane does, releasing Nrf2 to drive phase II transcription. The two are commonly stacked for that reason.

Pterostilbene activates Nrf2 and sirtuin signalling, overlapping with the antioxidant response element genes sulforaphane switches on. Their induction of phase II enzymes runs through the same transcriptional node.

Resveratrol raises Nrf2 nuclear translocation and NQO1 expression, the same output sulforaphane drives more strongly. Stacking the two widens the induction across polyphenol and isothiocyanate chemistry.

Myrosinase activity is ascorbate-dependent within a concentration window described in the plant enzymology literature. Ascorbate also influences whether hydrolysis yields the isothiocyanate or the nitrile side product. This is enzyme chemistry rather than a clinical outcome.

Inducing an enzyme only matters if its cofactor is available. FAD, made from riboflavin, is the prosthetic group of NQO1. Riboflavin status therefore sits underneath one of the classic readouts used to measure sulforaphane activity.

The pyridine nucleotide pool that NQO1 draws on is built from niacin. This is a cofactor supply relationship in established biochemistry, not a demonstrated additive clinical effect.

When myrosinase is destroyed by heat, conversion falls to the colonic microbiota, and human conversion varies widely between people. Supplementation with sulforaphane has itself been reported to shift microbial co-occurrence networks. The relationship runs in both directions and the size of the effect on conversion is not settled.

Because part of glucoraphanin conversion happens in the colon, anything that changes the resident community can change conversion. Inulin fermentation does that indirectly. No human study has quantified the knock-on effect on isothiocyanate exposure.

Sulforaphane works by turning up endogenous antioxidant and conjugating enzymes; tocopherol works stoichiometrically in the lipid phase. The two arms are complementary in mechanism. Exercise studies of broccoli-derived material report marker endpoints such as lipid peroxidation, not clinical outcomes.

Coenzyme Q10 is reduced and recycled at the membrane, and NQO1, one of the enzymes induced downstream of Nrf2, can reduce quinones including ubiquinone. The link is mechanistically clean and clinically untested as a pairing.

Both compounds are described as Nrf2 activators in cell and animal work. Whether two activators of the same transcription factor add, saturate or do neither in people has not been measured. Early by design.

Zinc availability sets how much functional metallothionein can be made from an induced transcript. The connection is inferred from established metal handling rather than from a combination study.

Sulforaphane is consumed by conjugation to glutathione and excreted through the mercapturic acid route, so sulfur amino acid supply matters. MSM contributes sulfur but has not been shown to feed that specific conjugation pool in people. Keep expectations low.

Activated charcoal adsorbs small organic molecules in the gut lumen without discriminating between them. Co-ingestion is a plausible way to reduce how much isothiocyanate reaches the circulation. This is a spacing consideration rather than a demonstrated interaction.